Novo Nordisk A/S NOVO B.CO · DKK

Health Care · Nasdaq Copenhagen · 🇩🇰 Denmark

Compare

272.80

+1.24%

Close of 9 Nov 2026, in DKK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in DKK, from our data supplier.

FY2025

Revenue

DKK 309.06bn

FY2016FY2025

Net income

DKK 102.43bn

FY2016FY2025

Free cash flow

DKK 28.99bn

FY2016FY2025

Shareholders' equity

DKK 194.05bn

FY2016FY2025

Income statement

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	DKK 309.06bn	DKK 290.40bn	DKK 232.26bn	DKK 176.95bn	DKK 140.80bn	DKK 126.95bn	DKK 122.02bn	DKK 111.83bn	DKK 111.70bn	DKK 111.78bn
Gross profit	DKK 250.28bn	DKK 245.88bn	DKK 196.50bn	DKK 148.51bn	DKK 117.14bn	DKK 106.01bn	DKK 101.93bn	DKK 94.21bn	DKK 94.06bn	DKK 94.60bn
Research and development	DKK 52.04bn	DKK 48.06bn	DKK 32.44bn	DKK 24.05bn	DKK 17.77bn	DKK 15.46bn	DKK 14.22bn	DKK 14.80bn	DKK 14.01bn	DKK 14.56bn
Operating income	DKK 130.84bn	DKK 128.34bn	DKK 102.57bn	DKK 74.81bn	DKK 58.64bn	DKK 54.13bn	DKK 52.48bn	DKK 47.25bn	DKK 48.97bn	DKK 48.43bn
Net income	DKK 102.43bn	DKK 100.99bn	DKK 83.68bn	DKK 55.52bn	DKK 47.76bn	DKK 42.14bn	DKK 38.95bn	DKK 38.63bn	DKK 38.13bn	DKK 37.92bn
Diluted earnings per share	23.02	22.63	18.77	12.24	10.42	9.05	8.22	8.00	7.73	7.53

Balance sheet

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Total assets	DKK 542.90bn	DKK 465.80bn	DKK 314.49bn	DKK 241.26bn	DKK 194.51bn	DKK 144.92bn	DKK 125.61bn	DKK 110.77bn	DKK 102.36bn	DKK 97.54bn
Cash and short-term investments	DKK 26.96bn	DKK 26.31bn	DKK 30.23bn	DKK 23.57bn	DKK 17.48bn	DKK 12.76bn	DKK 15.47bn	DKK 15.64bn	DKK 18.85bn	DKK 20.70bn
Total liabilities	DKK 348.86bn	DKK 322.31bn	DKK 207.93bn	DKK 157.77bn	DKK 123.76bn	DKK 81.60bn	DKK 68.02bn	DKK 58.93bn	DKK 52.54bn	DKK 52.27bn
Debt	DKK 130.96bn	DKK 102.79bn	DKK 27.01bn	DKK 25.78bn	DKK 26.64bn	DKK 10.36bn	DKK 4.48bn	DKK 515.0m	DKK 1.69bn	DKK 229.0m
Shareholders' equity	DKK 194.05bn	DKK 143.49bn	DKK 106.56bn	DKK 83.49bn	DKK 70.75bn	DKK 63.33bn	DKK 57.59bn	DKK 51.84bn	DKK 49.81bn	DKK 45.27bn
Shares outstanding	4,449m	4,463m	4,458m	4,537m	4,584m	4,658m	4,738m	4,828m	4,931m	5,034m

Cash flow

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Cash from operations	DKK 119.10bn	DKK 120.97bn	DKK 108.91bn	DKK 78.89bn	DKK 55.00bn	DKK 51.95bn	DKK 46.78bn	DKK 44.62bn	DKK 41.17bn	DKK 48.31bn
Capital spending	−DKK 90.11bn	−DKK 51.31bn	−DKK 38.90bn	−DKK 14.75bn	−DKK 7.38bn	−DKK 22.08bn	−DKK 11.23bn	−DKK 12.41bn	−DKK 8.65bn	−DKK 8.27bn
Free cash flow	DKK 28.99bn	DKK 69.66bn	DKK 70.01bn	DKK 64.13bn	DKK 47.62bn	DKK 29.87bn	DKK 35.55bn	DKK 32.21bn	DKK 32.52bn	DKK 40.05bn
Dividends paid	−DKK 51.76bn	−DKK 44.14bn	−DKK 31.77bn	−DKK 25.30bn	−DKK 21.52bn	−DKK 20.12bn	−DKK 19.41bn	−DKK 19.05bn	−DKK 18.84bn	−DKK 23.83bn

Latest quarters

By quarter end

	Jun 2026	Mar 2026	Dec 2025	Sept 2025	Jun 2025	Mar 2025	Dec 2024	Sept 2024
Revenue	DKK 78.49bn	DKK 96.82bn	DKK 79.14bn	DKK 74.98bn	DKK 76.86bn	DKK 78.09bn	DKK 85.68bn	DKK 71.31bn
Gross profit	DKK 61.39bn	DKK 83.22bn	DKK 64.00bn	DKK 57.07bn	DKK 64.01bn	DKK 65.20bn	DKK 72.66bn	DKK 60.00bn
Operating income	DKK 27.06bn	DKK 59.62bn	DKK 25.82bn	DKK 23.68bn	DKK 33.45bn	DKK 38.79bn	DKK 36.74bn	DKK 33.82bn
Net income	DKK 20.99bn	DKK 48.56bn	DKK 26.89bn	DKK 20.01bn	DKK 26.50bn	DKK 29.03bn	DKK 28.23bn	DKK 27.30bn
Diluted earnings per share	4.73	10.95	6.04	4.50	5.96	6.53	6.33	6.12
Cash from operations	DKK 55.20bn	DKK 24.08bn	DKK 7.62bn	DKK 46.11bn	DKK 40.78bn	DKK 24.59bn	DKK 12.30bn	DKK 43.85bn
Capital spending	−DKK 12.80bn	−DKK 12.04bn	−DKK 43.84bn	−DKK 15.41bn	−DKK 16.27bn	−DKK 14.59bn	−DKK 16.56bn	−DKK 12.12bn
Free cash flow	DKK 42.40bn	DKK 12.04bn	−DKK 36.22bn	DKK 30.69bn	DKK 24.51bn	DKK 10.01bn	−DKK 4.26bn	DKK 31.73bn
Total assets	DKK 594.94bn	DKK 559.22bn	DKK 542.90bn	DKK 512.29bn	DKK 482.15bn	DKK 489.16bn	DKK 465.80bn	DKK 397.44bn
Cash and short-term investments	DKK 44.98bn	DKK 21.63bn	DKK 26.96bn	DKK 32.58bn	DKK 18.93bn	DKK 41.55bn	DKK 26.31bn	DKK 74.88bn
Debt	DKK 140.13bn	DKK 146.38bn	DKK 123.72bn	DKK 101.21bn	DKK 99.27bn	DKK 118.72bn	DKK 97.36bn	DKK 56.97bn
Shareholders' equity	DKK 221.28bn	DKK 203.06bn	DKK 194.05bn	DKK 169.90bn	DKK 168.07bn	DKK 138.54bn	DKK 143.49bn	DKK 120.52bn

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	20.4%	19.5%	11.1%
Operating income	20.5%	19.3%	10.2%
Net income	22.6%	19.4%	11.4%

Average margins

Over each period

	1 year	3 years	5 years	10 years
Gross margin	82.8%	83.4%	83.4%	83.7%
Operating margin	43.2%	43.3%	43.0%	43.2%
Net margin	33.9%	34.0%	33.9%	33.7%

Valuation history

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Price to earnings	14.1	27.6	37.2	38.3	35.3	23.6	23.5	18.6	21.6	16.9
Price to sales	4.7	9.6	13.4	12.0	12.0	7.8	7.5	6.4	7.4	5.7

Dividends and splits

Per share, in the currency the company pays

Paid for 36 years. Last went ex-dividend on 14 Aug 2026.

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Paid in the year	11.70	11.65	9.90	7.075	5.575	4.675	4.30	4.075

2-for-1 split · 13 Sept 2023
5-for-1 split · 2 Jan 2014
2-for-1 split · 3 Dec 2007
5-for-1 split · 4 Apr 2001
2-for-1 split · 2 Jan 1997

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

Novo Nordisk A/S NOVO B.CO · DKK

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Latest quarters

Growth per year

Average margins

Valuation history

Dividends and splits

Sources and methodology